<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Both <z:chebi fb="0" ids="35664">statin</z:chebi> and <z:hpo ids='HP_0002045'>hypothermia</z:hpo> protect the brain from focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we sought to determine whether <z:chebi fb="0" ids="35664">statin</z:chebi> pretreatment enhances the efficacy of <z:hpo ids='HP_0002045'>hypothermia</z:hpo> and extends the therapeutic time window of <z:hpo ids='HP_0002045'>hypothermia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Rats were subjected to focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> for 2 h </plain></SENT>
<SENT sid="3" pm="."><plain>Initially, we tested the efficacy of <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> pretreatment (1 mg/kg, daily for 10 days before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>) and <z:hpo ids='HP_0002045'>hypothermia</z:hpo> (32-33 degrees C for 2 h at <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>) in combination, and then we examined the effects of <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> pretreatment on the therapeutic time window of <z:hpo ids='HP_0002045'>hypothermia</z:hpo> (3 or 6 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Both <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> (27.5+/-4.6) and <z:hpo ids='HP_0002045'>hypothermia</z:hpo> (25.9+/-6.3%) reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes significantly as compared with the control group (40.5+/-3.3%; p&lt;0.05 in each comparison) </plain></SENT>
<SENT sid="5" pm="."><plain>These two treatments in combination further decreased <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes (13.2+/-6.3%), and remarkably reduced the staining extents of Ox-42, and of inducible nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, <z:hpo ids='HP_0002045'>hypothermia</z:hpo> alone was found to be effective when applied at 3 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, but not when applied at 6 h </plain></SENT>
<SENT sid="7" pm="."><plain>However, <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> pretreatment and <z:hpo ids='HP_0002045'>hypothermia</z:hpo> led to a significant reduction in <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes even when <z:hpo ids='HP_0002045'>hypothermia</z:hpo> was applied at 6 h </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: It was found that <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> pretreatment strongly enhances <z:hpo ids='HP_0002045'>hypothermia</z:hpo>-induced neuroprotection and extends the treatment window after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Because both treatments are already known to be clinically feasible and safe, such a strategy would appear have merits for the treatment of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>